ArticleThe Lancet regional health. Europe2026
Trends in paediatric antiseizure-medication use and costs in France, 2014-2023: a nationwide population-based analysis.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporal trends in NSAID prescribing by office-based neurologists in France: a nationwide repeated cross-sectional study.Acta neurologica Belgica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epilepsy is the commonest chronic neurological disorder of childhood. In France, pregnancy-prevention rules and generic policies aim to improve safety and affordability of anti-seizure medications (ASM), but their paediatric impact is unknown. Tracking these patterns is key to assess policy effectiveness and to ensure safe, equitable, and sustainable access to treatment. We aimed to characterise nationwide temporal trends in paediatric ASM use, costs, generic uptake, and sex differences in France from 2014 to 2023. Methods: We conducted a retrospective drug-utilisation study using open-access OpenMedic files from the French National Health Data System. All dispensing of 24 ASMs to individuals <18 years during 2014-23 were retrieved by product code. Annual users, boxes, and costs were summarised; temporal trends used Spearman tests; multivariable logistic regression modelled sex differences; LASSO selected determinants of generic dispensing. Findings: Over the decade, 2,015,504 children consumed 15,748,141 ASM boxes, costing €274.4 million. Annual users increased 24% (from 174,889 to 216,607). Third-generation agents rose 70% (from 98,659 users per year to 168,290), whereas first- and second-generation agents fell 48% (from 1579 to 823) and 28% (from 87,929 to 63,038). Valproate use fell 37% overall (from 58,845 to 37,014) and 62% in girls (from 23,480 to 8975); lamotrigine and levetiracetam rose 49% (from 29,404 to 43,847) and 77% (from 37,290 to 65,940), respectively. Generics accounted for 11.2% of dispensing in 2014 (191,551 boxes) vs 20.2% in 2023 (455,934 boxes). Prescriptions by private psychiatrists and use of gabapentin, pregabalin, lamotrigine, and levetiracetam independently predicted generic uptake. ASM with available generic substitution would have cut 2023 spending by 8% (€3.88 million). Interpretation: Paediatric ASM practice in France is rapidly aligning with safer, newer ASM and sex-specific risk mitigation, yet generic penetration lacks. Targeted substitution strategies could release funds for innovative therapies without compromising seizure control. Funding: None.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.